Biogen Stock Price and Value Analysis

Biogen (NasdaqGS:BIIB) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Biogen to reach your target.

Target type

BIIB Free Cash Flow Trend

Free Cash Flow trendline for BIIB
Free Cash Flow trendline for Biogen
CSV

Based on historical returns, we believe that Biogen can grow its free cash at a rate of about 12%. That's positive!

AdvantagesDisadvantagesNeutral
  • This stock is available at a great discount!
  • This company is very stable.
  • This company is making money at a great rate!
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the BIIB Numbers

BIIB Price
(Biogen stock price per share)
$249.59
[?] BIIB Fair Price
(based on intrinsic value)
$803.15
[?] BIIB Safety Price (based on a variable margin of safety) $642.52
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 433% higher than other Healthcare stocks
[?] PE Ratio versus Industry 86% higher than other Biotechnology stocks
[?] Cash Yield 9.97%
[?] Free Cash Flow Jitter 60%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 5,453,103 shares shorted. With 147,285,114 shares available for purchase and an average trading volume over the past 10 trading days of 1,003,910, it would take at least 5.4 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2007 875045 735
2008 875045 1,282
2009 875045 833
2010 875045 1,400
2011 875045 1,506
2012 875045 1,664
2013 875045 2,136
2014 875045 2,762
2015 875045 3,771
2016 875045 4,473
2017 875045 4,487
2018 875045 6,161
2019 875045 6,953
2020 875045 4,022
2021 875045 3,388
2022 875045 1,085
2023 875045 1,204
2024 875045 2,605
2025 875045 1,988

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 19 fiscal years from 2007 to 2025 with positive net income, operating cash flow totaled $56,381 million against net income of $43,606 million, or 1.29 times.

In 2025, operating cash flow was 1.71 times net income, compared with 1.53 times for the earliest three years (2007 to 2009).

In 2025, capital expenditures were $154 million, 7.0% of operating cash flow of $2,205 million, which leaves an estimated $2,051 million after capex. Across the 19 years with reported capex, it averaged 6.7% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2007 638 1,019 284 1.60
2008 783 1,562 276 2.00
2009 970 1,075 166 1.11
2010 1,005 1,625 173 1.62
2011 1,234 1,728 208 1.40
2012 1,380 1,880 255 1.36
2013 1,862 2,345 246 1.26
2014 2,935 2,942 20.5 1.00
2015 3,547 3,919 13.1 1.10
2016 3,703 4,587 38.6 1.24
2017 2,539 4,551 3 1.79
2018 4,431 6,188 58.2 1.40
2019 5,889 7,079 515 1.20
2020 4,001 4,230 425 1.06
2021 1,556 3,640 258 2.34
2022 3,047 1,384 240 0.45
2023 1,161 1,547 277 1.33
2024 1,632 2,876 154 1.76
2025 1,293 2,205 154 1.71

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2013 to 2022 with dividend or share repurchase facts, estimated free cash flow totaled $39,237 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 10 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $28,103 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2022, cash spent repurchasing shares was $750 million, 69.1% of estimated free cash flow of $1,085 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2013 2,136 n/a 400 400 18.7%
2014 2,762 n/a 887 887 32.1%
2015 3,771 n/a 5,000 5,000 132.6%
2016 4,473 n/a 1,000 1,000 22.4%
2017 4,487 n/a 1,365 1,365 30.4%
2018 6,161 n/a 4,353 4,353 70.6%
2019 6,953 n/a 5,868 5,868 84.4%
2020 4,022 n/a 6,679 6,679 166.1%
2021 3,388 n/a 1,800 1,800 53.1%
2022 1,085 n/a 750 750 69.1%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $3,172 million in 2007 and $9,891 million in 2025, a compound annual growth rate of 6.5% over 18 years.

Revenue rose 2.2% from 2024 to 2025.

Our estimated free cash flow was $1,988 million in 2025, 20.1% of revenue. In 2007 the estimated margin was 23.2%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2007 3,172 735 23.2%
2008 4,098 1,282 31.3%
2009 4,377 833 19.0%
2010 4,716 1,400 29.7%
2011 5,049 1,506 29.8%
2012 5,516 1,664 30.2%
2013 6,932 2,136 30.8%
2014 9,703 2,762 28.5%
2015 10,764 3,771 35.0%
2016 11,449 4,473 39.1%
2017 12,274 4,487 36.6%
2018 13,453 6,161 45.8%
2019 14,378 6,953 48.4%
2020 13,445 4,022 29.9%
2021 10,982 3,388 30.9%
2022 10,173 1,085 10.7%
2023 9,836 1,204 12.2%
2024 9,676 2,605 26.9%
2025 9,891 1,988 20.1%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $3,009 million against total liabilities of $11,183 million, or 26.9% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 38.0% of total assets in 2025, compared with 31.2% in 2008, an increase of 6.8 percentage points.

Stockholders equity was $18,257 million in 2025, compared with $5,834 million in 2008, a rise of 212.9%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 8.6% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2008 8,479 622 2,645 5,834
2009 8,552 582 2,290 6,262
2010 8,092 760 2,643 5,449
2011 9,050 515 2,623 6,427
2012 10,130 571 3,166 6,964
2013 11,863 603 3,243 8,621
2014 14,315 1,205 3,501 10,814
2015 19,505 1,308 10,130 9,375
2016 22,877 2,327 10,748 12,129
2017 23,653 1,574 11,055 12,598
2018 25,289 1,225 12,257 13,032
2019 27,234 2,914 13,895 13,339
2020 24,619 1,331 13,933 10,686
2021 23,877 2,261 12,918 10,960
2022 24,554 3,419 11,166 13,388
2023 26,845 1,050 12,045 14,799
2024 28,049 2,375 11,333 16,716
2025 29,440 3,009 11,183 18,257

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $249.59, our model's value equals that price if free cash flow grows an average of -8.9 percent a year over the 10 projection years. Our model assumes 12.5 percent a year for this stock, so the price implies growth of -8.9 percent, which is below the 12.5 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

A negative rate means the price matches our model's value only if free cash flow shrinks by that average each year over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $3,677 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $199.67 -15.0%
Current price $249.59 -8.9%
20 percent above the current price $299.51 -4.7%
Our model (stored fair price) $803.15 12.5%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

At $249.59, the stock is under our safe value of $642.52, against a fair value estimate of $803.15.

Free cash flow was positive in all 19 fiscal years we have for Biogen under its current SEC filer.

Comparing the first and last three years of data, average free cash flow rose sharply: $950 million at the start and $1,932 million most recently.

Free cash flow is volatile from year to year, with a variability measure of 60%.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

No dividend yield is recorded for Biogen in our data.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 433% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 86% above the average for stocks in the Biotechnology industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Biotechnology industry, the ones closest in market capitalization to Biogen, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Biogen (BIIB) 36,894 108.0 - 10.0% 69% below
Neurocrine Biosciences (NBIX) 15,240 22.3 - - 469% above
Bio-Techne Corporation (TECH) 11,416 66.7 0.3% 1.4% 90% above
Repligen Corporation (RGEN) 10,471 - - - 397% above
Amgen (AMGN) 235,643 25.3 2.3% 4.5% 11% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 875045.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: BIIB annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in BIIB

Does Biogen have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: BIIB

This example shows how we apply the Trendshare checklist to BIIB: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 249.59
    • Market cap: $37B
    • EPS: 2.31
  2. Step 2 — Valuation checks

    • P/E: 108.048
    • FCF yield: 10.0%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.